

Icotrokinra outperforms oral competitor deucravacitinib in a head-to-head plaque psoriasis trial

Market Event Summary

ICONIC-ADVANCE findings support icotrokinra's potential as a preferred oral treatment for plaque psoriasis

ICONIC-ADVANCE study design

- ICONIC-**ADVANCE 1** (N = 774) and **ADVANCE 2** (N = 731) are randomized, double-blind, placebo-controlled, multicenter, H2H Phase 3 trials evaluating the efficacy and safety of icotrokinra compared with both placebo and deucravacitinib in moderate to severe plaque PsO patients aged 12 or older.
- The studies' co-primary endpoints were IGA 0/1 and PASI 90 vs. placebo at week 16. Key secondary endpoints included measuring superiority to deucravacitinib at weeks 16 and 24.

Results

- On September 17, 2025, Johnson & Johnson Innovative Medicine announced the results of the ICONIC-ADVANCE 1 & 2 trials. Icotrokinra demonstrated significantly higher rates of IGA 0/1 and PASI 90 vs. placebo at week 16 and vs. deucravacitinib at week 16 and 24 (*Results were presented at EADV 2025 congress by L. Stein Gold*).
- Icotrokinra also demonstrated significantly higher rates of complete skin clearance vs. placebo at week 16 and vs. deucravacitinib at week 16 and 24.
- Icotrokinra's adverse events (AE) profile was similar to placebo through week 16. Overall, AE rates through week 24 were lower with icotrokinra than deucravacitinib.

Clarivate's takeaways



Icotrokinra approval expected in the United States and Europe in 2026

- Icotrokinra has been filed for regulatory approval in the United States and Europe based on four pivotal Phase 3 studies conducted as part of the ICONIC clinical development program: ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2. Based on the regulatory status, we expect icotrokinra's approval in the United States in Q2 2026 and in Europe in Q3 2026.
- Once approved, Icotrokinra is expected to gain a competitive advantage over deucravacitinib, positioning it as an emerging first-line oral option for patients with moderate disease.



Icotrokinra is aiming to redefine the SOC for moderate to severe plaque PsO

- **Key opinion leaders interviewed by Clarivate** say that icotrokinra has the potential to set a new standard in the treatment of plaque psoriasis as the first targeted oral peptide to selectively block the IL-23 receptor with efficacy and safety similar to an injectable biologic.
- J&J is further strengthening icotrokinra's clinical profile by seeking to demonstrate its superiority over injectable biologic ustekinumab in the Phase 3 ICONIC-ASCEND. This trial is groundbreaking as it is the first head-to-head study comparing an oral pill with an injectable biologic in psoriasis. Given the safety and convenience of oral administration over injectable therapies, this shift has the potential to enhance patient satisfaction.

About the authors



Aayushi Sharma

Associate Healthcare Research & Data Analyst

DRG Commercial Solutions

Before joining Clarivate, Ms. Sharma was a senior business analyst in competitive intelligence at AdametNext. She has contributed to multiple secondary and strategic projects that track competitors' regulatory, clinical, and commercial activities in immunology and oncology. She holds a master's degree with a specialization in pharmacoinformatics from the NIPER.



Mohit Nasa, M.B.A.

Senior Manager, Healthcare Research & Data Analytics, Immune & Inflammation

DRG Commercial Solutions

Mr. Nasa has authored content on such indications as systemic lupus erythematosus, psoriasis, asthma, COPD, and rheumatoid arthritis. Prior to joining Clarivate, he worked as a senior business analyst at Novartis, where he was responsible for end-to-end market assessment and related projects for the company's asthma brand, Xolair. Mr. Nasa holds a bachelor's degree in pharmacy and an M.B.A. in marketing and CRM from Amity Business School in India.

Clarivate coverage of Psoriasis

- Disease Landscape & Forecast: Psoriasis (G7), providing comprehensive market insights.
- Epidemiology: Total and diagnosed prevalence data for various population segments of psoriasis across the mature markets.
- Treatment Algorithms: Claims Data Analysis (US): Explores the current treatment journey of pediatric psoriasis through longitudinal patient claims data.
- Treatment Algorithms: Claims Data Analysis (US): Explores the current treatment journey of adult psoriasis through longitudinal patient claims data.
- Current Treatment: Physician Insights (EU): Provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use in psoriasis market.
- Unmet Need: Provides insights into areas of unmet need in Psoriasis (US / EU), including an Excel- based target product profile simulator.



Think forward™

Have a question?

lsh.support@clarivate.com
clarivate.com

+1 215 386 0100 (U.S.)

+44 (0) 20 7433 4000 (Europe)

About Clarivate

Clarivate is the leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit [clarivate.com](https://www.clarivate.com)

© 2025 Clarivate. All rights reserved

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.